To address this, we investigated whether the more stable CNP analogue vosoritide (VO) reduces arrhythmia at cellular and organ levels in mice with STZ-induced type 1 diabetes (50 μg/g, i.p. for 5 days). Here, CNP is linked to cardiac arrhythmia.